Introduction: The aim of the study was to analyse the influence of renal impairment on the pharmacokinetic parameters (PK) of mycophenolic acid (MPA) and its glucuronide metabolite (MPAG) in renal transplant recipients. Material and methods: The study included 43 adult patients during the maintenance period (> 6 months) following renal transplantation, treated with mycophenolate mofetil (MMF), calcineurin inhibitors (CNI) (tacrolimus or cyclosporine) and steroids. The study compared patients with normal renal function (n = 17; creatinine clearance (C cr ) > 60 ml/min) and with renal impairment (n = 26; C cr < 60 ml/min). Areas under the 4-h curve (AUC 0-4 h ) of MPA and MPAG were determined using a validated HPLC method. Results: The renal impairment group showed significantly increased AUC 0-4 h and pre-dose (C 0 ) for MPAG compared to patients with normal renal function and increased MPA C 0 . However, there was no significant difference in MPA AUC 0-4 h between patients with renal impairment and patients with normal renal function. In multivariate analysis some MPA and MPAG PK parameters were correlated with sex, CNI co-administered and body weight. Conclusions: Although MPAG is an inactive metabolite, its accumulation in patients with renal impairment can be unfavourable. The results of our study indicate that solely MPA C 0 determination in patients receiving MMF may be insufficient in clinical practice because of great inter-patient variability of this PK parameter caused mainly by enterohepatic recirculation.
Introduction
Mycophenolate mofetil (MMF, CellCept®) is the most widely used antiproliferative immunosuppressive drug in patients after solid organ transplantation, often co-administered with calcineurin inhibitors (CNI) and corticosteroids [1] .
Pharmacologically inactive MMF after oral administration is rapidly and entirely hydrolysed into an active metabolite -mycophenolic acid (MPA). The MPA is a non-nucleoside, uncompetitive and reversible inosine monophosphate dehydrogenase inhibitor, which participates in guanosine triphosphates de novo synthesis. As a consequence, MPA inhibits the proliferation of T and B lymphocytes, preventing the acute rejection of a transplanted organ as well as decreasing the frequency of late rejection after one year and consecutive years [2, 3] . The MPA undergoes enterohepatic recirculation. It is converted into an inactive phenyl glucuronide (MPAG), which is excreted into bile and hydrolysed into MPA in the presence of β-glucuronidase, produced by intestinal bacteria, and subsequently reabsorbed in the intestines. It was found that, on average, the enterohepatic recirculation takes part in about 40% (10-60%) of the entire MPA exposure [4] .
The MPA as well as MPAG pharmacokinetics (PK) show great inter-patient variability depending on race, sex, concomitant clinical condition (e.g. kidney or liver impairment, diseases with coexisting hypoalbuminaemia), interactions with drugs influencing the PK of MPA and MPAG, time elapsed after renal transplantation and pharmacogenetic factors [4] [5] [6] .
The MPAG is eliminated mainly by the kidney and the increase of its concentration may indicate the deterioration of renal function. Compared to patients with normal renal function, MPAG concentration in patients with impaired renal function is several times greater. Uncontrolled MPAG concentration increase causes MPA displacement from protein compounds and the increase of free MPA, which might be the cause of higher pharmacological activity of the drug and the intensification of its adverse effects. The influence of renal failure on total MPA concentration is still unclear. There are no unequivocal recommendations for MMF dosing in patients with renal failure [4, 7, 8] .
The aim of the study was to analyse the influence of renal impairment on the PK of MPA and its metabolite MPAG in renal transplant recipients.
Material and methods
Forty-three adult patients during the maintenance period (> 6 months) following renal transplantation receiving MMF in combination with cyclosporine (CsA) (n = 21) or tacrolimus (Tac) (n = 22) and corticosteroids were considered. The MMF dose varied from 0.50 g/day to 2.00 g/day and was administered most often twice a day. The study included patients with normal renal function (n = 16; creatinine clearance (C cr ) > 60 ml/min) and with renal impairment (n = 27, C cr < 60 ml/min). Clinical characteristics of the patients are presented in Table I . Blood samples were collected into tubes containing EDTA at the following time points: before the morning dose of MMF (C 0 ), and subsequently 40 min, 1, 2, 3, 4 h after dosing.
Plasma MPA and MPAG concentrations were determined using a high-performance liquid chromatography (HPLC) method described previously [9, 10] . Briefly, the separation was performed using a Supelcosil TM LC-18-DB column. The mobile phase consisted of acetonitrile and orthophosphoric acid (50 mmol/l) in a 50 : 50 ratio and indomethacin was used as an internal standard. The MPAG plasma concentration was estimated after MPAG enzymatic hydrolysis into MPA in β-glucuronidase presence (activity 89.4 U/ml). The MPAG concentrations were Number of patients All (n = 43) C cr > 60 ml/min (n = 17) C cr < 60 ml/min (n = 26) The analysis method had a linear range of 0.1-25.0 μg/ml and 10-250 μg/ml for MPA and MPAG, respectively. Accuracy of MPA and MPAG batches ranged from 97.4% to 106.4% and from 96.5% to 116.6%, respectively, and the precision, expressed as the percentage of coefficient of variation (% CV), ranged from 0.8% to 6.9% and from 0.9% to 17.4%, respectively.
The following PK parameters for MPA and MPAG were calculated: pre-dose concentration (C 0 ), maximum concentration (C max ) and area under the plasma concentration -time curve from 0 to 4 h (AUC 0-4 h ) using the linear trapezoidal rule. Interpatient variability was assessed as % CV. C cr was estimated using the Cockcroft-Gault formula.
All statistical tests were performed using Statistica software version 8.0 and p value < 0.05 was considered significant. Chi-square test was used for the evaluation of qualitative data. Normality was determined by Shapiro-Wilk W test. Data were evaluated by the Mann-Whitney test and Spearman correlation analysis. Multivariate analysis was performed to evaluate the influence of various clinical determinants on MPA and MPAG PK parameters. For multivariate analysis both PK parameters corrected and uncorrected for MMF dose were examined. In the remaining analyses only dose-corrected values were considered.
The study was performed following the recommendations of the Declaration of Helsinki and approved by the Bioethical Commission at the Poznan University of Medical Sciences. Informed consent was obtained from all patients prior to initiating the study.
Results
The two groups of patients (with C cr above or below 60 ml/min) were comparable for sex, age, time elapsed after renal transplantation, body weight, MMF dose and for number of patients receiving CsA or Tac. For groups with normal and impaired renal function, medians of serum creatinine were 1.3 mg/dl and 2.1 mg/dl, respectively, and median C cr 75.2 ml/min and 44.9 ml/min, respectively.
The MPA C 0 values were significantly higher in patients with impaired renal function than in patients with normal renal function. However, AUC 0-4 h and C max values were not significantly different between the two groups ( Figure 1 , Table II) . Moreover, the values of PK parameters for MPAG (AUC 0-4 h , C 0 and C max ) were also significantly higher in patients with impaired renal function (Table II) . Comparable differences for MPA and MPAG PK parameters were observed between groups in particular immunosuppressive regimens; however, the differences for MPA C 0 values were barely significant (Table III) .
In univariate analysis, MPAG PK parameters (AUC 0-4 h , C 0 , C max ) were negatively correlated with C cr and positively correlated with serum creatinine (Figure 2 ). Within MPA PK parameters, only C 0 was negatively correlated with C cr and positively correlated with serum creatinine. Similar correlations were found in particular immunosuppressive regimens, although the serum creatinine correlation with MPA C 0 in patients receiving MMF in combination with CsA was statistically insignificant (Table IV) .
In multivariate analysis the results are consistent with univariate analysis. Additionally, some MPA and MPAG PK parameters were correlated with sex, CNI co-administered and body weight. No correlations with proteinuria were observed (Tables V and VI) .
For MPA and MPAG PK parameters, high CV values were observed, which in patients with impaired (Table II) .
Discussion
In our study we analysed the influence of renal function on MPA and MPAG PK in patients during the maintenance period following renal transplantation. The concentrations of both MMF metabolites (MPA and MPAG) varied widely, particularly in patients with impaired renal function, despite MMF dose correction. Similar variability was also presented by other authors [11] [12] [13] .
Total drug exposure is best demonstrated by AUC 0-12 h . In clinical practice this parameter is difficult to assess, especially in patients treated in clinics during the maintenance period following renal transplantation. In our study, blood samples were collected within 4 h after drug administration due to the short duration of the patient's stay in hospital during a routine appointment in a transplant 
Value of p** C cr > 60 ml/min C cr < 60 ml/min C cr > 60 ml/min C cr < 60 ml/min (n = 9) (n = 13) (n = 8) (n = clinic. The MPA C 0 is the most often used parameter in clinical practice. Its value may be considerably influenced by MPAG enterohepatic recirculation, resulting in the second MPA plasma concentration peak (C max2 ) approximately 6-12 h after drug administration. In our study, higher MPA C 0 as well as MPAG C 0 , C max and AUC 0-4 h values were observed in patients with impaired renal function regardless of CNI used, whereas there were no differences in the values of the other MPA PK parameters (C max and AUC 0-4 h ). Elevated MPA C 0 values may indicate intensified enterohepatic recirculation due to MPAG concentration increase in patients with impaired renal function. The correlations between renal function and MPAG concentrations as well as MPA C 0 suggest that the cause of the differences observed between two groups is the dependence of MPAG concentration and indirectly MPA C 0 on renal function. The results concerning MPAG are consistent with the literature. However, the influence of renal function on MPA PK parameters is still unclear. Similar results concerning MPA and MPAG PK parameters were obtained by Gonzalez-Roncero et al. [14] . The authors demonstrated not only the influence of renal function on MPA C 0 and MPAG AUC but also its lack on MPA AUC. The studies by Zanker et al. [15] , Morgera et al. [16] and Weber et al. [17] also observed higher MPAG AUC in renal transplant recipients with lower C cr than in patients with normal glomerular filtration. However, values of MPA AUC did not differ significantly. On the other hand, the results for MPA obtained by Mohammadpur et al. [18] were different. According to this study, significantly higher MPA AUC 0-12 h values along with unchanged C 0 and significantly higher MPA C max2 values were observed in patients with impaired renal function. The authors also found a negative correlation for C cr and MPA AUC. The use of abbreviated MPA profiles in our study may be the reason for different AUC results compared with the Mohammadpur et al. study. The abbreviated profiles do not include MPA C max2 associated with enterohepatic recirculation. In contrast to these studies, van Hest et al. [19] and Weber et al. [20] observed a total MPA concentration decrease in patients with impaired renal function. It was suggested that the concentration decrease was due to the accumulation of MPAG, which displaced MPA from its protein compounds, increasing free MPA concentration and its clearance. The controversies concerning the influence of renal failure on MPA concentration values may be explained by Naesens et al. [21] . The authors observed increased MPA and MPAG concentration values in patients with moderately reduced renal function (C cr ranging from 30 ml/min to 60 ml/min), whereas decreased total MPA concentration values were observed in patients with severe graft dysfunction (C cr < 30 ml/ min), similarly as in the study by van Hest et al. [19] . This may explain the lack of differences in MPA AUC 0-4 h and C max values between groups with C cr Pharmacokinetics of mycophenolic acid and its phenyl glucuronide metabolite in kidney transplant recipients with renal impairment above or below 60 ml/min in our study, because the group with impaired renal function included patients with moderate as well as with severe graft dysfunction. Nevertheless, our study showed higher MPA C 0 values in patients with C cr < 60 ml/ min, which may indicate intensified enterohepatic recirculation in patients with impaired renal function as found in the study by Mohammadpur et al. [18] . Proteinuria may also be considered as a factor influencing MPA and MPAG PK parameters. Naesens et al. [21] demonstrated correlations between MPA PK parameters and proteinuria. However, in our study in the multivariate analysis no relations between MPA and MPAG PK parameters were observed. It may be due to the small number of patients (n = 9) with proteins determined in urine.
MPAG -7-O-mycophenolic acid glucuronide, PK -pharmacokinetic, C0 -pre-dose concentration, CNI -calcineurin inhibitor
In conclusion, renal failure, irrespective of immunosuppressive regimen, influences the MPAG PK parameters and MPA C 0 by increasing the values in patients with impaired renal function. The results of our study indicate that solely MPA C 0 determination in patients receiving MMF may be insufficient in clinical practice because of great inter-patient variability of this PK parameter caused mainly by enterohepatic recirculation. It may lead to wrong decisions concerning the pharmacotherapy, particularly in patients with impaired renal function. It seems to us that the monitoring of MPA and MPAG AUC may allow MMF dosage regimens to be optimized, and as a result improve the early prevention of adverse effects in these patients.
